Bararia Akash, Das Amlan, Mitra Sangeeta, Banerjee Sudeep, Chatterjee Aniruddha, Sikdar Nilabja
Human Genetics Unit, Indian Statistical Institute, Kolkata 700108, India.
Department of Biochemistry, Royal Global University, Assam 781035, India.
World J Gastrointest Oncol. 2023 Sep 15;15(9):1505-1519. doi: 10.4251/wjgo.v15.i9.1505.
Pancreatic cancer (PanCa) presents a catastrophic disease with poor overall survival at advanced stages, with immediate requirement of new and effective treatment options. Besides genetic mutations, epigenetic dysregulation of signaling pathway-associated enriched genes are considered as novel therapeutic target. Mechanisms beneath the deoxyribonucleic acid methylation and its utility in developing of epi-drugs in PanCa are under trails. Combinations of epigenetic medicines with conventional cytotoxic treatments or targeted therapy are promising options to improving the dismal response and survival rate of PanCa patients. Recent studies have identified potentially valid pathways that support the prediction that future PanCa clinical trials will include vigorous testing of epigenomic therapies. Epigenetics thus promises to generate a significant amount of new knowledge of biological and medical importance. Our review could identify various components of epigenetic mechanisms known to be involved in the initiation and development of pancreatic ductal adenocarcinoma and related precancerous lesions, and novel pharmacological strategies that target these components could potentially lead to breakthroughs. We aim to highlight the possibilities that exist and the potential therapeutic interventions.
胰腺癌（PanCa）是一种灾难性疾病，晚期患者总体生存率很低，迫切需要新的有效治疗方案。除基因突变外，信号通路相关富集基因的表观遗传失调被视为新的治疗靶点。胰腺癌中脱氧核糖核酸甲基化的机制及其在表观遗传药物开发中的应用正在研究中。表观遗传药物与传统细胞毒性治疗或靶向治疗联合使用，有望改善胰腺癌患者令人沮丧的反应和生存率。最近的研究已经确定了潜在有效的途径，这支持了未来胰腺癌临床试验将大力测试表观基因组治疗的预测。因此，表观遗传学有望产生大量具有生物学和医学重要性的新知识。我们的综述可以确定已知参与胰腺导管腺癌及相关癌前病变发生和发展的表观遗传机制的各个组成部分，针对这些组成部分的新型药理学策略可能会带来突破。我们旨在强调存在的可能性和潜在的治疗干预措施。
